| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
DPPS does not have a specific biological target as a drug. It is a structural component of cell membranes and is used as a model phospholipid in biophysical studies. In liposome formulations, it contributes to the formation of lipid bilayers. Its anionic nature (due to the phosphate and serine groups) influences the surface charge of the liposomes, which can affect their interaction with cells, proteins, and other molecules. This property is exploited in the preparation of catanionic vesicles for drug delivery and other applications.
|
|---|---|
| ln Vitro |
In vitro, DPPS is used as a lipid component in cell membrane studies and in the preparation of catanionic vesicles and liposomes. As an anionic diacyl phospholipid, it contributes to the negative charge of cell membranes. It is used in biophysical studies to investigate membrane properties, such as fluidity, permeability, and protein-lipid interactions. In liposome formulations, it can be used to encapsulate drugs or other molecules for delivery or for studying membrane interactions.
|
| ln Vivo |
In vivo activity of DPPS is not typically studied, as it is a lipid component rather than a bioactive drug. However, liposomes containing DPPS can be administered to animals for drug delivery or imaging purposes. The lipid's ability to form stable bilayers and its biocompatibility make it suitable for such applications. Its effects in vivo would be related to the encapsulated payload or the liposome's interaction with biological systems, rather than the lipid itself.
|
| Enzyme Assay |
In vitro enzyme/receptor binding (non-cell) assays using DPPS are typically biophysical studies of membrane interactions. A standard protocol for studying protein-lipid interactions: liposomes are prepared with DPPS and other lipids (e.g., phosphatidylcholine). A protein of interest (e.g., a membrane-binding protein) is incubated with the liposomes. The binding of the protein to the liposomes is assessed by measuring the change in fluorescence, by centrifugation to separate bound and unbound protein, or by surface plasmon resonance. These studies help to understand how proteins interact with negatively charged membranes.
|
| Cell Assay |
In vitro cell-based assays for DPPS are not common, as it is a lipid used for membrane studies. However, liposomes containing DPPS can be used to deliver drugs or other molecules to cells. A standard protocol for liposome-mediated delivery: liposomes are prepared with DPPS and other lipids, encapsulating a drug or a fluorescent dye. Cells are cultured and treated with the liposomes for a period of time. The uptake of the liposomes and the delivery of the payload are assessed by measuring the fluorescence or by analyzing the cellular effects of the drug. This approach is used to study liposome-cell interactions and to optimize liposome formulations for drug delivery.
|
| Animal Protocol |
In vivo animal experiments using DPPS are typically related to liposome-based drug delivery. A standard protocol: liposomes containing DPPS and a drug are administered intravenously to mice. The biodistribution of the liposomes and the drug is assessed by measuring the concentration of the drug in various tissues over time using HPLC or mass spectrometry. The therapeutic efficacy of the drug-loaded liposomes is evaluated in disease models (e.g., cancer or infection). The DPPS component contributes to the stability and circulation time of the liposomes.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of DPPS are not a primary focus of study, as it is a lipid component. When formulated in liposomes, the pharmacokinetics of the liposomes are determined by their size, charge, and surface properties. DPPS contributes to the negative charge of the liposomes, which can affect their circulation time and biodistribution. The lipid itself is likely to be metabolized and incorporated into endogenous lipid pools.
|
| Toxicity/Toxicokinetics |
Toxicity of DPPS is considered low, as it is a naturally occurring phospholipid analog. It is biocompatible and biodegradable. When used in liposome formulations, the toxicity is more likely to be related to the encapsulated drug or other components of the formulation. Standard laboratory safety precautions should be followed when handling the compound.
|
| References |
|
| Additional Infomation |
DPPS is a synthetic, anionic diacyl phospholipid used as a lipid component in cell membrane studies. It can be used in the preparation of catanionic vesicles and liposomes. It is a valuable tool for studying membrane biophysics, protein-lipid interactions, and for developing liposome-based drug delivery systems. It is not a drug and has no clinical use or approval status. It is commercially available from chemical suppliers for research purposes only.
|
| Molecular Formula |
C38H73NO10P-.NA+
|
|---|---|
| Molecular Weight |
757.95052
|
| Exact Mass |
757.487
|
| Elemental Analysis |
C, 60.22; H, 9.71; N, 1.85; Na, 3.03; O, 21.11; P, 4.09
|
| CAS # |
145849-32-7
|
| Related CAS # |
12-Dipalmitoyl-sn-glycero-3-PS-d62 sodium;327178-94-9
|
| PubChem CID |
46891791
|
| Appearance |
White to off-white solid powder
|
| LogP |
9.315
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
39
|
| Heavy Atom Count |
51
|
| Complexity |
861
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](C(=O)[O-])N)OC(=O)CCCCCCCCCCCCCCC.[Na+]
|
| InChi Key |
GTLXLANTBWYXGW-CEGNZRHUSA-M
|
| InChi Code |
InChI=1S/C38H74NO10P.Na/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-36(40)46-31-34(32-47-50(44,45)48-33-35(39)38(42)43)49-37(41)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2;/h34-35H,3-33,39H2,1-2H3,(H,42,43)(H,44,45);/q;+1/p-1/t34-,35+;/m1./s1
|
| Chemical Name |
sodium;(2S)-2-azaniumyl-3-[[(2R)-2,3-di(hexadecanoyloxy)propoxy]-oxidophosphoryl]oxypropanoate
|
| Synonyms |
DPPS; 1,2-DPPS; PS 16:0/16:0; 1,2-Dipalmitoyl-sn-glycero-3-phospho-L-serine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :< 1 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3193 mL | 6.5967 mL | 13.1935 mL | |
| 5 mM | 0.2639 mL | 1.3193 mL | 2.6387 mL | |
| 10 mM | 0.1319 mL | 0.6597 mL | 1.3193 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
